motixafortide (Pending FDA Approval)

Brand and Other Names:Aphexda
  • Print

Dosing & Uses

Multiple Myeloma

Pending FDA approval for stem cell mobilization (in addition to G-CSF) for autologous bone marrow transplantation in patients with multiple myeloma

Next:

Pharmacology

Mechanism of Action

CXCR4 inhibitor; CXCR4 controls mobilization and trafficking of hematopoietic stem cells (HSCs) through signaling pathways CXCL12 in bone marrow stromal cells binds to CXCR4 on HSCs and retain them in the bone marrow

Motixafortide blocks this interaction between CXCL12 ligand and CXCR4, which leads to stem cell mobilization to the peripheral blood for collection by apheresis and storage for autologous transplantation

Previous
Next:

Images

No images available for this drug.
Previous
Next:

Patient Handout

A Patient Handout is not currently available for this monograph.
Previous
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.